Literature DB >> 26026052

The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition.

Payel Chatterjee1, Gaurav S Choudhary2, Turkeyah Alswillah3, Xiahui Xiong4, Warren D Heston5, Cristina Magi-Galluzzi6, Junran Zhang4, Eric A Klein7, Alexandru Almasan8.   

Abstract

Exposure to genotoxic agents, such as ionizing radiation (IR), produces DNA damage, leading to DNA double-strand breaks (DSB); IR toxicity is augmented when the DNA repair is impaired. We reported that radiosensitization by a PARP inhibitor (PARPi) was highly prominent in prostate cancer cells expressing the TMPRSS2-ERG gene fusion protein. Here, we show that TMPRSS2-ERG blocks nonhomologous end-joining (NHEJ) DNA repair by inhibiting DNA-PKcs. VCaP cells, which harbor TMPRSS2-ERG and PC3 cells that stably express it, displayed γH2AX and 53BP1 foci constitutively, indicating persistent DNA damage that was absent if TMPRSS2-ERG was depleted by siRNA in VCaP cells. The extent of DNA damage was enhanced and associated with TMPRSS2-ERG's ability to inhibit DNA-PKcs function, as indicated by its own phosphorylation (Thr2609, Ser2056) and that of its substrate, Ser1778-53BP1. DNA-PKcs deficiency caused by TMPRSS2-ERG destabilized critical NHEJ components on chromatin. Thus, XRCC4 was not recruited to chromatin, with retention of other NHEJ core factors being reduced. DNA-PKcs autophosphorylation was restored to the level of parental cells when TMPRSS2-ERG was depleted by siRNA. Following IR, TMPRSS2-ERG-expressing PC3 cells had elevated Rad51 foci and homologous recombination (HR) activity, indicating that HR compensated for defective NHEJ in these cells, hence addressing why TMPRSS2-ERG alone did not lead to radiosensitization. However, the presence of TMPRSS2-ERG, by inhibiting NHEJ DNA repair, enhanced PARPi-mediated radiosensitization. IR in combination with PARPi resulted in enhanced DNA damage in TMPRSS2-ERG-expressing cells. Therefore, by inhibiting NHEJ, TMPRSS2-ERG provides a synthetic lethal interaction with PARPi in prostate cancer patients expressing TMPRSS2-ERG. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26026052      PMCID: PMC4529796          DOI: 10.1158/1535-7163.MCT-14-0865

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  50 in total

1.  Unraveling the complexities of DNA-dependent protein kinase autophosphorylation.

Authors:  Jessica A Neal; Seiji Sugiman-Marangos; Pamela VanderVere-Carozza; Mike Wagner; John Turchi; Susan P Lees-Miller; Murray S Junop; Katheryn Meek
Journal:  Mol Cell Biol       Date:  2014-03-31       Impact factor: 4.272

2.  MDC1 interacts with Rad51 and facilitates homologous recombination.

Authors:  Junran Zhang; Zhefu Ma; Alejandro Treszezamsky; Simon N Powell
Journal:  Nat Struct Mol Biol       Date:  2005-09-25       Impact factor: 15.369

3.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Authors:  Jirina Bartkova; Zuzana Horejsí; Karen Koed; Alwin Krämer; Frederic Tort; Karsten Zieger; Per Guldberg; Maxwell Sehested; Jahn M Nesland; Claudia Lukas; Torben Ørntoft; Jiri Lukas; Jiri Bartek
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

4.  Inhibition of homologous recombination by DNA-dependent protein kinase requires kinase activity, is titratable, and is modulated by autophosphorylation.

Authors:  Jessica A Neal; Van Dang; Pauline Douglas; Marc S Wold; Susan P Lees-Miller; Katheryn Meek
Journal:  Mol Cell Biol       Date:  2011-02-07       Impact factor: 4.272

5.  TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.

Authors:  Kyung Park; James T Dalton; Ramesh Narayanan; Christopher E Barbieri; Michael L Hancock; David G Bostwick; Mitchell S Steiner; Mark A Rubin
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

6.  The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen.

Authors:  T M Gottlieb; S P Jackson
Journal:  Cell       Date:  1993-01-15       Impact factor: 41.582

7.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Authors:  Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

8.  Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.

Authors:  Subrata Ray; Alex Almasan
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

9.  A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest.

Authors:  Zhihui Feng; Junran Zhang
Journal:  Nucleic Acids Res       Date:  2011-09-27       Impact factor: 16.971

10.  A noncatalytic function of the ligation complex during nonhomologous end joining.

Authors:  Jessica Cottarel; Philippe Frit; Oriane Bombarde; Bernard Salles; Aurélie Négrel; Stéphanie Bernard; Penny A Jeggo; Michael R Lieber; Mauro Modesti; Patrick Calsou
Journal:  J Cell Biol       Date:  2013-01-21       Impact factor: 10.539

View more
  17 in total

Review 1.  The ETS family of oncogenic transcription factors in solid tumours.

Authors:  Gina M Sizemore; Jason R Pitarresi; Subhasree Balakrishnan; Michael C Ostrowski
Journal:  Nat Rev Cancer       Date:  2017-04-28       Impact factor: 60.716

2.  Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells.

Authors:  Moureq Alotaibi; Khushboo Sharma; Tareq Saleh; Lawrence F Povirk; Eric A Hendrickson; David A Gewirtz
Journal:  Radiat Res       Date:  2016-03-02       Impact factor: 2.841

3.  Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.

Authors:  Ling-Jiao Zou; Qiu-Ping Xiang; Xiao-Qian Xue; Cheng Zhang; Chen-Chang Li; Chao Wang; Qiu Li; Rui Wang; Shuang Wu; Yu-Lai Zhou; Yan Zhang; Yong Xu
Journal:  Acta Pharmacol Sin       Date:  2019-05-16       Impact factor: 6.150

Review 4.  Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer.

Authors:  Yi-Xin Chen; Li-Ming Tan; Jian-Ping Gong; Ma-Sha Huang; Ji-Ye Yin; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Acta Pharmacol Sin       Date:  2021-02-15       Impact factor: 6.150

5.  Integrated genomic profiling expands clinical options for patients with cancer.

Authors:  Nike Beaubier; Martin Bontrager; Robert Huether; Catherine Igartua; Denise Lau; Robert Tell; Alexandria M Bobe; Stephen Bush; Alan L Chang; Derick C Hoskinson; Aly A Khan; Emily Kudalkar; Benjamin D Leibowitz; Ariane Lozachmeur; Jackson Michuda; Jerod Parsons; Jason F Perera; Ameen Salahudeen; Kaanan P Shah; Timothy Taxter; Wei Zhu; Kevin P White
Journal:  Nat Biotechnol       Date:  2019-09-30       Impact factor: 68.164

Review 6.  Landscape of gene fusions in epithelial cancers: seq and ye shall find.

Authors:  Chandan Kumar-Sinha; Shanker Kalyana-Sundaram; Arul M Chinnaiyan
Journal:  Genome Med       Date:  2015-12-18       Impact factor: 11.117

7.  Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?

Authors:  Steve S Huang; Warren D W Heston
Journal:  Theranostics       Date:  2017-04-01       Impact factor: 11.556

Review 8.  Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors.

Authors:  Musaffe Tuna; Christopher I Amos; Gordon B Mills
Journal:  Oncotarget       Date:  2019-03-12

Review 9.  Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies.

Authors:  Paul Lesueur; François Chevalier; Jean-Baptiste Austry; Waisse Waissi; Hélène Burckel; Georges Noël; Jean-Louis Habrand; Yannick Saintigny; Florence Joly
Journal:  Oncotarget       Date:  2017-07-07

Review 10.  Drugging the Cancers Addicted to DNA Repair.

Authors:  Jac A Nickoloff; Dennie Jones; Suk-Hee Lee; Elizabeth A Williamson; Robert Hromas
Journal:  J Natl Cancer Inst       Date:  2017-11-01       Impact factor: 11.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.